Skip to content

C

DRUG18 trials

Sponsors

Moderna Inc., Apellis Pharmaceuticals Inc., GlaxoSmithKline Biologicals, Sanofi Pasteur, Sanofi Pasteur, Sanofi Pasteur

Conditions

Acute lower respiratory infectionC3 glomerulopathy (C3G) or immune complex membranoproliferative glomerulonephritis (IC-MPGN)Cesarean Section ComplicationsChronic spontaneous urticariaFluid LoadingGeneralized Myasthenia GravisGeneralized Myasthenia Gravis and Ocular Myasthenia GravisHealthy

Phase 1

Phase 2

Phase 3

Tranexamic Acid Versus Placebo for the Reduction of Blood Loss in Total Hip Replacement Surgery
CompletedNCT01199627
Basque Health ServiceHip Replacement, Total
Start: 2011-03-31End: 2013-02-28Updated: 2013-02-07
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALE)
Active, not recruitingCTIS2023-504625-39-00
Apellis Pharmaceuticals Inc.C3 glomerulopathy (C3G) or immune complex membranoproliferative glomerulonephritis (IC-MPGN)
Start: 2023-05-18Target: 66Updated: 2026-01-08
A parallel-group, prevention, Phase III, modified double-blind, 2-arm, study to investigate the immunogenicity and describe the safety of a quadrivalent meningococcal conjugate vaccine (MenACYW conjugate vaccine) compared with Nimenrix® when administered in a 1+1 schedule in healthy infants and toddlers at 6 and 12 months of age
RecruitingCTIS2023-508177-85-00
Sanofi PasteurHealthy volunteers (Meningococcal infection)
Start: 2024-03-12Target: 840Updated: 2026-01-26
A Phase IIIb, Open-label, Multi-center Study to Evaluate the Immunogenicity and Safety of a Booster Dose and Describe the Immune Persistence of MenACYW Conjugate Vaccine with 5- and/or 10-year Booster Doses in Children and Adolescents who had been Primed with MenACYW Conjugate Vaccine as Toddlers
Active, not recruitingCTIS2023-510145-25-00
Sanofi Pasteur, Sanofi PasteurMeningococcal infection
Start: 2022-08-23Target: 209Updated: 2025-06-25

Phase 4

Unknown Phase

Related Papers